Summary
In an open-label, nonrandomised, noncomparative treatment investigational new drug (IND) study, 536 patients with either the acquired immunodeficiency syndrome (AIDS) or positive human immunodeficiency virus (HIV) serology and low CD4 counts were administered rifabutin 300 mg/day prophylactically in an attempt to prevent or delay the development of Mycobacterium avium complex (MAC) bacteraemia. The purpose of the study was to allow HIV-positive and AIDS patients wider access to rifabutin for MAC prophylaxis while the application for marketing approval was under review. Patients included in the study had either a diagnosis of AIDS and a CD4 count of ≤ 200 cells/µl or were HIV-positive with a CD4 count of ≤ 100 cells/µl (but without an AIDS-defining event). Patients eligible for inclusion were to have no evidence of disseminated MAC disease as evaluated by a blood culture taken within 21 days before treatment. 19 of 533 evaluable patients (3.6%) with negative baseline cultures developed MAC bacteraemia. In addition, MAC was isolated from the sputum of 1 other patient. Fever, night sweats, diarrhoea and abdominal pain remained absent in 57 to 71% of patients. CD4 counts and Karnofsky scores generally remained stable or improved in more than 80% of patients. The most common adverse events (those with a frequency > 1%) attributable to rifabutin were leucopenia (7.1%), rash (5.2%), nausea and diarrhoea (4.1% each), headache (3.0%) and abdominal pain (2.2%). The results of this study, within the limitations of the study design, are consistent with the findings of phase III placebo-controlled clinical trials showing that rifabutin prevents or delays MAC bacteraemia in HIV-positive or AIDS patients with low CD4 counts. Rifabutin appears to be well tolerated with a relatively low incidence of (mostly minor) adverse events.
Similar content being viewed by others
References
Snider Jr DE, Hopewell PC, Mills J, et al. Mycobacterioses and the acquired immunodeficiency syndrome. Am Rev Respir Dis 1987; 136: 492–6
Chaisson RE, Hopewell PC. Mycobacteria and AIDS mortality. Am Rev Respir Dis 1989; 189: 1–3
Horsburgh CR, Selik RM. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1989; 139: 4–7
Nightingale SD, Byrd LT, Southern PM, et al. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165: 1082–5
Masur H. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 1993; 329(12): 898–904
National Institutes of Health. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med 1984; 100: 92–106
Armstrong D, Gold JWM, Dryjanski J, et al. Treatment of infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1985; 103: 738–43
Chaisson RE, Moore RD, Richman DD, et al. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. Am Rev Respir Dis 1992; 146: 285–9
Jacobson MA, Hopewell PC, Yajko DM, et al. Natural history of disseminated Mycobacterium avium complex infection in AIDS. J Infect Dis 1991; 164: 994–8
Horsburgh CR, Havlik JA, Ellis DA, et al. Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am Rev Respir Dis 1991; 144: 557–9
Ellner JJ, Goldberger MJ, Parenti DM. Mycobacterium avium infection and AIDS: a therapeutic dilemma in rapid evolution. J Infect Dis 1991; 163: 1326–35
Benson C. Disseminated Mycobacterium avium complex disease in patients with AIDS. AIDS Res Hum Retroviruses 1994; 10(8): 913–6
Heifets LB, Lindholm-Levy PJ, Comstock RD. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am Rev Respir Dis 1992; 145: 856–8
Dautzenberg B, Saint Marc T, Meyohas MC, et al. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med 1993; 153: 368–72
Heifets LB, Iseman MD. Individualized therapy versus standard regimens in the treatment of Mycobacterium avium infections. Am Rev Respir Dis 1991; 144: 1–2
Young LS, Wiviott L, Wu M, et al. Azithromycin for treatment of Mycobacterium aviumintracellulare complex infection in patients with AIDS. Lancet 1991; 338: 1107–9
Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121: 905–11
Kemper CA, Meng TC, Nussbaum J, et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a fourdrug oral regimen: rifampin, ethambutol, clofazimine and ciprofloxacin. Ann Inter Med 1992; 116: 466–72
Agins BD, Berman DS, Spicehandler D, et al. Effect of combined therapy with ansamycin, clofazimine, ethambutol, and isoniazid for Mycobacterium avium infection in patients with AIDS. J Infect Dis 1989; 159: 784–7
Hoy J, Mijch A, Sandland M, et al. Quadruple-drug therapy for Mycobacterium avium-intracellulare bacteremia in AIDS patients. J Infect Dis 1990; 161: 801–5
Horsburgh CR, Havlik JA, Metchock BG, et al. Oral therapy of disseminated Mycobacterium avium complex infection in AIDS relieves symptoms and is well tolerated [abstract]. Am Rev Respir Dis 1991; 143 Suppl: A115
Dautzenberg B, Truffot C, Mignon A, et al. Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Tubercle 1991; 72: 168–75
Heifets LB, Iseman MD, Lindholm-Levy PJ. Bacteriostatic and bactericidal effects of rifabutin (ansamycin LM 427) on Mycobacterium avium clinical isolates. In: Casai M, editor. Mycobacteria of clinical interest. Amsterdam: Elsevier Science, 1986: 180–3
Saito H, Sato K, Tomioka H. Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex. Tubercle 1988; 69: 187–92
Gangadharam PR, Perumal VK, Podapati NR, et al. In vivo activity of amikacin alone or in combination with clofazamine or rifabutin or both against acute experimental Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1988; 32: 1500–3
Brogden RN, Fitton A. Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47(6): 983–1009
Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993; 329(12): 828–33
Karnofsky DA, Abelmann WH, Craver LF, et al. The use of the notrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1: 6345–6
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Di Pietro, N., Kamal, M. Rifabutin for the Prevention of Mycobacterium avium Complex Bacteraemia in AIDS and HIV-Positive Patients with CD4 Counts ≤ 200 Cells/µl. Clin. Drug Invest. 11, 1–10 (1996). https://doi.org/10.2165/00044011-199611010-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-199611010-00001